WHO ending hydroxycholorquine trial for COVID

Latest News

WHO ending hydroxycholorquine trial for COVID

Saturday, July 04, 2020

Print this page Email A Friend!


BERLIN, Germany (AP) — The World Health Organisation says it is ending a trial into whether anti-malaria drug hydroxychloroquine helps patients hospitalized with COVID-19.

WHO said Saturday it has “accepted the recommendation” from the committee overseeing the trial to discontinue testing of hydroxychloroquine and lopinavir/ritonavir, a drug combination used to treat HIV/AIDS. The drugs were being compared with standard care for hospitalized patients.

WHO says a review of the interim results showed hydroxychloroquine and lopinavir/ritonavir “produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care.”

The agency adds that while there was no “solid evidence” of increased mortality for hospitalized patients given the drugs, there were “some associated safety signals in the clinical laboratory findings” of an associated trial.

WHO says the decision won't affect possible trials on patients who aren't hospitalised, or on those receiving the drugs before potential exposure to the coronavirus or shortly afterward.


Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at http://bit.ly/epaper-login


ADVERTISEMENT




POST A COMMENT

HOUSE RULES

1. We welcome reader comments on the top stories of the day. Some comments may be republished on the website or in the newspaper � email addresses will not be published.

2. Please understand that comments are moderated and it is not always possible to publish all that have been submitted. We will, however, try to publish comments that are representative of all received.

3. We ask that comments are civil and free of libellous or hateful material. Also please stick to the topic under discussion.

4. Please do not write in block capitals since this makes your comment hard to read.

5. Please don't use the comments to advertise. However, our advertising department can be more than accommodating if emailed: advertising@jamaicaobserver.com.

6. If readers wish to report offensive comments, suggest a correction or share a story then please email: community@jamaicaobserver.com.

7. Lastly, read our Terms and Conditions and Privacy Policy



comments powered by Disqus
ADVERTISEMENT

Poll

ADVERTISEMENT
ADVERTISEMENT

Today's Cartoon

Click image to view full size editorial cartoon
ADVERTISEMENT